The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
PPTA 2014 Business Forum +
Registration now open!
The 2014 PPTA Business Forum will be held October 26th in Philadelphia, Pennsylvania.
[This event is for PPTA Members Only]Read More
Initiation of the Five Week Enrollment Period for the Medicare IVIG Demonstration Project +
August 8, 2014—PPTA is pleased to announce the initiation of the five week enrollment period for the Medicare IVIG Demonstration Project beginning today.Read More
EHC Video on European Recommendations for Haemophilia Treatment +
Please view this timely video from the European Haemophilia Consortium on "European recommendations for the treatment of haemophilia and other bleeding disorders."Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly.
Read the current issue.